Export financials
Chembio Diagnostics (CEMI)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

Chembio Diagnostics Financial Statements 2022-2009 | CEMI
Annual Financial Statements Chembio Diagnostics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
12.6 M | 27.7 M | 90.7 M | 77.3 M | 81.7 M | 101 M | 72.2 M | 51.3 M | 37.3 M | 30.3 M | 37.8 M | 26.5 M | - | - |
Shares |
32.3 M | 24.3 M | 19.1 M | 17 M | 14.4 M | 12.3 M | 10.6 M | 9.63 M | 9.53 M | 8.99 M | 7.99 M | 7.87 M | 62.1 M | - |
Historical Prices |
0.39 | 1.14 | 4.75 | 4.56 | 5.66 | 8.2 | 6.8 | 5.33 | 3.91 | 3.37 | 4.73 | 3.36 | - | - |
Net Income |
-23.3 M | -33.9 M | -25.5 M | -13.7 M | -7.87 M | -6.37 M | -13.3 M | -2.4 M | -1.14 M | 531 K | 941 K | 6.21 M | 2.51 M | - |
Revenue |
49.5 M | 47.8 M | 32.5 M | 34.5 M | 34.6 M | 24 M | 17.9 M | 24.3 M | 27.6 M | 29.5 M | 25.6 M | 19.4 M | - | - |
Cost of Revenue |
38.6 M | 34.5 M | 23.9 M | 22.4 M | 22.6 M | 12.9 M | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | 6.58 M | 12.1 M | 12 M | 1.44 M | 725 K | 1.87 M | 10.8 M | 12.3 M | 10.8 M | 9.39 M | 8.1 M | - |
Operating Income |
-23.6 M | -31.1 M | -23.1 M | -13.3 M | -7.98 M | -6.48 M | -7.57 M | -3.55 M | -1.55 M | 1 M | 1.45 M | 1.09 M | 2.57 M | - |
Interest Expense |
- | - | - | - | - | 2.94 K | - | 836 | - | 335 | 9.5 K | 18.6 K | 14.7 K | - |
EBITDA |
-21.1 M | -28.1 M | -20.4 M | -11.4 M | -7.08 M | -5.21 M | -6.43 M | -2.18 M | -811 K | 1.61 M | 1.98 M | 1.53 M | 2.86 M | - |
Operating Expenses |
- | - | 28.5 M | 24.7 M | 41.4 M | 30.5 M | 25.4 M | 27.8 M | 12.4 M | 11.3 M | 9.34 M | 8.3 M | 5.53 M | - |
General and Administrative Expenses |
24.3 M | 24.8 M | 21 M | 16.1 M | 11.1 M | 8.96 M | 7.6 M | 7.66 M | 7.53 M | 5.46 M | 4.85 M | 3.42 M | 2.94 M | - |
All numbers in USD currency
Quarterly Income Statement Chembio Diagnostics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | 32.3 M | 30.2 M | 30.1 M | 30.1 M | 26.7 M | 20.2 M | 20.2 M | 20.2 M | 20.1 M | 18.9 M | 17.2 M | 17.7 M | 16.9 M | 16.9 M | 17.2 M | 17.2 M | 14.2 M | 14.2 M | 13.3 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 12 M | 11.1 M | 9.67 M | 9.63 M | 9.63 M | 9.63 M | 9.63 M | 9.62 M | 9.61 M | 9.61 M | 9.56 M | 9.34 M | 9.32 M | 9.32 M | 9.26 M | 8.06 M | 8.04 M | 8 M | 7.99 M | 63.5 M | 7.92 M | 63.3 M | 63.1 M | 62.3 M |
Net Income |
- | -6.7 M | -6.95 M | -8.79 M | - | -6.37 M | -9.06 M | -4.5 M | - | -5.54 M | -7.84 M | -5 M | - | -3.78 M | -3.19 M | -2.82 M | - | -2.31 M | -1.73 M | -652 K | -2 M | -585 K | -2.17 M | -1.62 M | -2.56 M | -2.14 M | -8.35 M | -304 K | -649 K | -437 K | -664 K | -647 K | - | -271 K | -146 K | -225 K | - | 717 K | -241 K | 317 K | - | -292 K | 309 K | 433 K | - | 476 K | 195 M | -142 K |
Revenue |
- | 11.2 M | 9.16 M | 18.8 M | - | 12.1 M | 6.46 M | 8.72 M | - | 10.3 M | 5.11 M | 6.86 M | - | 9.72 M | 9.59 M | 8.3 M | - | 9.38 M | 8.72 M | 7.72 M | 5.99 M | 7.59 M | 4.11 M | 6.33 M | 4.25 M | 3.75 M | 3.27 M | 6.6 M | 4.42 M | 6.89 M | 6.72 M | 6.23 M | - | 7.31 M | 7.42 M | 5.81 M | - | 9.62 M | 5.39 M | 6.68 M | - | 5.01 M | 6.08 M | 6.65 M | - | 5.92 M | 3.61 M | 3.64 M |
Cost of Revenue |
- | 9.66 M | 8.09 M | 15.2 M | - | 7.9 M | 4.04 M | 3.55 M | - | 7.47 M | 5.67 M | 4.37 M | - | 6.65 M | 6.69 M | 4.77 M | - | 6.77 M | 5.94 M | 4.43 M | - | 4.06 M | 2.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.44 M | 3.52 M | 1.91 M | 3.11 M | 725 K | 1.95 M | 1.58 M | 3.17 M | 1.87 M | 2.91 M | 3.02 M | 2.69 M | - | 2.65 M | 2.98 M | 2.27 M | - | 4.06 M | 2.28 M | 2.69 M | - | 1.73 M | 2.57 M | 3.33 M | - | 2.67 M | 2.05 B | 1.93 M |
Operating Income |
- | -5.99 M | -6.22 M | -8.05 M | - | -5.63 M | -8.34 M | -3.86 M | - | -4.91 M | -7.27 M | -4.42 M | - | -3.61 M | -3.3 M | -3.1 M | - | -2.33 M | -1.75 M | -654 K | - | -589 K | -2.18 M | -1.63 M | - | -2.14 M | -2.39 M | -468 K | - | -579 K | -898 K | -875 K | - | -262 K | -233 K | -383 K | - | 1.07 M | -380 K | 487 K | - | -485 K | 512 K | 720 K | - | 479 K | 197 M | -139 K |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.07 K | - | 3.85 K | 7.72 K | 13.4 K | - | - | 1.31 K | - | - | 749 | - | - | - | - | - | - | - | - | - | 335 | - | 2.82 K | 2.32 K | 2.44 K | - | 4.87 K | 4.03 M | 4.44 K |
EBITDA |
- | -4.12 M | -5.01 M | -7.45 M | - | -3.44 M | -6.95 M | -3.17 M | - | -2.85 M | -5.83 M | -3.68 M | - | -1.94 M | -2.55 M | -2.74 M | - | -1.67 M | -1.31 M | -431 K | - | 423 K | -1.41 M | -1.15 M | - | -1.27 M | -1.81 M | -177 K | - | 403 K | -232 K | -530 K | - | 274 K | 111 K | -210 K | - | 1.52 M | -97.4 K | 627 K | - | -80.5 K | 782 K | 850 K | - | 801 K | 414 M | -26.9 K |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.4 M | - | 11.7 M | 10.5 M | 8.37 M | - | 4.11 M | 4.09 M | 4.73 M | - | 4.1 M | 3.97 M | 3.63 M | - | 3.49 M | 3.92 M | 3.56 M | - | 2.91 M | 3.22 M | 2.66 M | - | 2.98 M | 2.66 M | 2.21 M | - | 2.21 M | 2.06 M | 2.61 M | - | 2.19 M | 1.85 B | 2.07 M |
General and Administrative Expenses |
- | 5.55 M | 5.25 M | 6.95 M | - | 5.95 M | 6 M | 6.09 M | - | 5.35 M | 4.4 M | 4.16 M | - | 4.46 M | 4.1 M | 4.01 M | - | 3.03 M | 2.55 M | 2.41 M | - | 2.31 M | 2.11 M | 2.49 M | - | 1.83 M | 1.6 M | 2 M | - | 1.92 M | 2.16 M | 1.98 M | - | 1.94 M | 1.95 M | 1.46 M | - | 1.38 M | 1.16 M | 1.16 M | - | 1.21 M | 1.08 M | 1.23 M | - | 949 K | 688 M | 775 K |
All numbers in USD currency
Main types of financial statements Chembio Diagnostics CEMIFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Chembio Diagnostics plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
ICON Public Limited Company
ICLR
|
$ 168.33 | 3.88 % | $ 13.2 B | ||
|
IDEXX Laboratories
IDXX
|
$ 527.07 | 1.67 % | $ 42.4 B | ||
|
Illumina
ILMN
|
$ 293.69 | 7.56 % | $ 45.5 B | ||
|
IQVIA Holdings
IQV
|
$ 266.09 | 3.05 % | $ 45.7 B | ||
|
Laboratory Corporation of America Holdings
LH
|
$ 308.65 | 0.05 % | $ 25.7 B | ||
|
Lantheus Holdings
LNTH
|
$ 100.19 | 0.23 % | $ 6.76 B | ||
|
Medpace Holdings
MEDP
|
$ 620.51 | 3.51 % | $ 17.9 B | ||
|
Mettler-Toledo International
MTD
|
$ 1 541.63 | 3.73 % | $ 31.8 B | ||
|
Myriad Genetics
MYGN
|
$ 4.58 | 0.88 % | $ 424 M | ||
|
ENDRA Life Sciences
NDRA
|
$ 6.31 | 4.13 % | $ 4.97 M | ||
|
NeoGenomics
NEO
|
$ 19.13 | 3.57 % | $ 2.45 B | ||
|
Neogen Corporation
NEOG
|
$ 13.01 | 7.08 % | $ 2.83 B | ||
|
National Research Corporation
NRC
|
$ 20.78 | 2.11 % | $ 465 M | ||
|
Natera
NTRA
|
$ 425.64 | 3.73 % | $ 58.2 B | ||
|
OPKO Health
OPK
|
$ 1.57 | 0.64 % | $ 1.18 B | ||
|
Pacific Biosciences of California
PACB
|
$ 2.87 | 12.99 % | $ 861 M | ||
|
Koninklijke Philips N.V.
PHG
|
$ 23.91 | 0.04 % | $ 22.7 B | ||
|
Precipio
PRPO
|
$ 24.0 | 3.76 % | $ 38.5 M | ||
|
Personalis
PSNL
|
$ 16.4 | 0.74 % | $ 1.46 B | ||
|
Quidel Corporation
QDEL
|
$ 12.14 | 12.72 % | $ 511 M | ||
|
QIAGEN N.V.
QGEN
|
$ 45.79 | 2.34 % | $ 9.95 B | ||
|
RadNet
RDNT
|
$ 70.63 | 1.0 % | $ 5.31 B | ||
|
Senseonics Holdings
SENS
|
$ 10.31 | 4.35 % | $ 430 M | ||
|
Sotera Health Company
SHC
|
$ 18.55 | 1.81 % | $ 5.27 B | ||
|
Neuronetics
STIM
|
$ 2.2 | 1.85 % | $ 145 M | ||
|
Thermo Fisher Scientific
TMO
|
$ 676.76 | 3.35 % | $ 255 B | ||
|
Twist Bioscience Corporation
TWST
|
$ 205.0 | 8.66 % | $ 12.3 B | ||
|
VolitionRx Limited
VNRX
|
$ 0.23 | 0.35 % | $ 28.9 M | ||
|
Waters Corporation
WAT
|
$ 440.12 | 3.51 % | $ 26.2 B | ||
|
Exagen
XGN
|
$ 8.46 | 3.55 % | $ 182 M | ||
|
Syneos Health
SYNH
|
- | - | $ 4.46 B | ||
|
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | ||
|
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M | ||
|
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | ||
|
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | ||
|
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | ||
|
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | ||
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | ||
|
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | ||
|
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | ||
|
Brainsway Ltd.
BWAY
|
$ 12.23 | 1.35 % | $ 415 M | ||
|
Trinity Biotech plc
TRIB
|
$ 5.77 | 1.41 % | $ 2.07 B | ||
|
Surmodics
SRDX
|
- | - | $ 608 M | ||
|
Heska Corporation
HSKA
|
- | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M | ||
|
Fluidigm Corporation
FLDM
|
- | 1.08 % | $ 308 M |